| 1 |
33783376 | eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma. | 2021 Sep 1 |
1 |
| 2 |
29492203 | Protein biosynthesis, a target of sorafenib, interferes with the unfolded protein response (UPR) and ferroptosis in hepatocellular carcinoma cells. | 2018 Feb 2 |
2 |
| 3 |
29538717 | Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways. | 2018 May 3 |
1 |
| 4 |
27840968 | Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus. | 2017 Jan |
3 |
| 5 |
22929805 | Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. | 2012 Oct 15 |
2 |
| 6 |
21487053 | Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. | 2011 Jun |
1 |
| 7 |
21768474 | Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. | 2011 Aug 20 |
1 |
| 8 |
20054642 | Synergistic activity of letrozole and sorafenib on breast cancer cells. | 2010 Nov |
1 |